Combining anti-CD3 treatment with the blockade of the CXCR3/CXCL10 axis using ACT-777991, a CXCR3 antagonist, further preserves B-cell damage and synergistically increases persistent remission in experimental models of type 1 diabetes. Here, CXCR3 is linked to type 1 diabetes mellitus.